PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines
- 23 July 2018
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 172 (1) , 23-32
Abstract
Purpose PARP-3 is member of the PARP family of poly (ADP-ribose) polymerases involved in ADPribosylation. PARPs are involved in the basic mechanisms of DNA repair. PARP3, a critical player for efficient mitotic progression, is required for the stabilization of the mitotic spindle by regulation of the mitotic components, NuMA and Tankyrase 1. Methods The sensitization effect of vinorelbine on PARP3 inhibition-induced cytotoxicity was assessed by the SRB assay. The contribution of programed cell death and cell cycle arrest to the sensitization effect were determined by assessing changes in Annexin V, a marker of apoptosis. Alterations in cell cycle progression were assessed by cell cycle analysis. We used immunofluorescence to assess the effect of vinorelbine and/or PARP3 inhibitors on tubulin and microtubule depolarization. The PARP3 chemiluminescent assay kit was used for PARP3 activity. Results PARP3 inhibitors sensitize breast cancer cells to vinorelbine, a vinca alkaloid used in the treatment of metastatic breast cancer. Olaparib which was originally described as a PARP1 and 2 inhibitor has recently been shown to be a potent PARP3 inhibitor while ME0328 is a more selective PARP3 inhibitor. The combination of vinorelbine with nontoxic concentrations of ME0328 or olaparib reduces vinorelbine resistance by 10 and 17 fold, respectively, potentiating vinorelbine-induced arrest at the G2/M boundary. In addition, PARP3 inhibition potentiates vinorelbine interaction with tubulin. Furthermore, olaparib or ME0328 potentiates vinorelbine-induced PARP3 inhibition, mitotic arrest, and apoptosis. Conclusion Our results indicated this approach with PARP3 inhibitors and vinorelbine is unique and promising for breast cancer patients with metastases. This combination could significantly increase the survival of breast cancer patients with metastases.Keywords
Funding Information
- The Cancer Research Society (01713)
This publication has 42 references indexed in Scilit:
- A Systematic Review of Vinorelbine for the Treatment of Breast CancerThe Breast Journal, 2013
- Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and BeyondFrontiers in Pharmacology, 2013
- The microtubule poison vinorelbine kills cells independently of mitotic arrest and targets cells lacking the APC tumour suppressor more effectivelyJournal of Cell Science, 2012
- Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor XenograftMolecular Cancer Therapeutics, 2011
- Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progressionProceedings of the National Academy of Sciences, 2011
- PARP-3 and APLF Function Together to Accelerate Nonhomologous End-JoiningMolecular Cell, 2011
- Safety and Efficacy of Vinorelbine in the Treatment of Non-Small Cell Lung CancerClinical Medicine Insights: Oncology, 2011
- Synthetic lethality: General principles, utility and detection using genetic screens in human cellsFEBS Letters, 2010
- PARP inhibition in BRCA-mutated breast and ovarian cancersThe Lancet, 2010
- The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical TargetsMolecular Cell, 2010